• Ultragenyx Pharmaceutical Inc RARE.OQ reported a quarterly adjusted loss of $1.39​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.52. The mean expectation of nineteen analysts for the quarter was for a loss of $1.29 per share. Wall Street expected results to range from $-1.96 to -98 cents per share.

• Revenue rose 29.4% to $164.88 million from a year ago; analysts expected $155.39 million.

• Ultragenyx Pharmaceutical Inc's reported EPS for the quarter was a loss of $1.39​.

• The company reported a quarterly loss of $133.39 million.

• Ultragenyx Pharmaceutical Inc shares had risen by 3.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.3% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $85.50

This summary was machine generated from LSEG data February 13 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)